# Citizens Financial Group Inc: financial statements, quarterly

CFG · NYSE · CIK 759944 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cfg.md) · [Financials](/companies/cfg/financials.md) · [Filings](/companies/cfg/filings.md) · [Insiders](/companies/cfg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cfg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [310](/filings/0000759944-24-000176.md) | [324 d](/filings/0000759944-26-000028.md) | [367](/filings/0000759944-25-000070.md) | [402](/filings/0000759944-25-000108.md) | [367](/filings/0000759944-25-000153.md) | [397 d](/filings/0000759944-26-000028.md) | [367](/filings/0000759944-26-000101.md) | [383](/filings/0000759944-26-000148.md) | [452](/filings/0000759944-25-000153.md) | [433 d](/filings/0000759944-26-000028.md) | [415](/filings/0000759944-26-000101.md) | [451](/filings/0000759944-26-000148.md) |
| Interest expense | $m | [1,073](/filings/0000759944-23-000149.md) | [1,188 d](/filings/0000759944-24-000039.md) | [1,168](/filings/0000759944-24-000090.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [119](/filings/0000759944-24-000176.md) | [16.0 d](/filings/0000759944-26-000028.md) | [96.0](/filings/0000759944-25-000070.md) | [88.0](/filings/0000759944-25-000108.md) | [88.0](/filings/0000759944-25-000153.md) | [107 d](/filings/0000759944-26-000028.md) | [95.0](/filings/0000759944-26-000101.md) | [118](/filings/0000759944-26-000148.md) | [135](/filings/0000759944-25-000153.md) | [149 d](/filings/0000759944-26-000028.md) | [133](/filings/0000759944-26-000101.md) | [168](/filings/0000759944-26-000148.md) |
| Net income | $m | [430](/filings/0000759944-24-000176.md) | [189 d](/filings/0000759944-26-000028.md) | [334](/filings/0000759944-25-000070.md) | [392](/filings/0000759944-25-000108.md) | [382](/filings/0000759944-25-000153.md) | [401 d](/filings/0000759944-26-000028.md) | [373](/filings/0000759944-26-000101.md) | [436](/filings/0000759944-26-000148.md) | [494](/filings/0000759944-25-000153.md) | [528 d](/filings/0000759944-26-000028.md) | [517](/filings/0000759944-26-000101.md) | [587](/filings/0000759944-26-000148.md) |
| Diluted EPS | $ per share | [0.85](/filings/0000759944-24-000176.md) | not reported | [0.65](/filings/0000759944-25-000070.md) | [0.78](/filings/0000759944-25-000108.md) | [0.77](/filings/0000759944-25-000153.md) | not reported | [0.77](/filings/0000759944-26-000101.md) | [0.92](/filings/0000759944-26-000148.md) | [1.05](/filings/0000759944-25-000153.md) | not reported | [1.13](/filings/0000759944-26-000101.md) | [1.30](/filings/0000759944-26-000148.md) |
| Basic EPS | $ per share | [0.85](/filings/0000759944-24-000176.md) | not reported | [0.66](/filings/0000759944-25-000070.md) | [0.79](/filings/0000759944-25-000108.md) | [0.77](/filings/0000759944-25-000153.md) | not reported | [0.78](/filings/0000759944-26-000101.md) | [0.93](/filings/0000759944-26-000148.md) | [1.06](/filings/0000759944-25-000153.md) | not reported | [1.14](/filings/0000759944-26-000101.md) | [1.31](/filings/0000759944-26-000148.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [225](/filings/0000759944-23-000149.md) | [222](/filings/0000759944-25-000013.md) | [220](/filings/0000759944-24-000090.md) | [220](/filings/0000759944-24-000148.md) | [220](/filings/0000759944-24-000176.md) | [218](/filings/0000759944-26-000028.md) | [220](/filings/0000759944-25-000070.md) | [218](/filings/0000759944-25-000108.md) | [223](/filings/0000759944-25-000153.md) | [226](/filings/0000759944-26-000148.md) | [228](/filings/0000759944-26-000101.md) | [234](/filings/0000759944-26-000148.md) |
| Total liabilities | $bn | [202](/filings/0000759944-23-000149.md) | [198](/filings/0000759944-25-000013.md) | [197](/filings/0000759944-24-000090.md) | [196](/filings/0000759944-24-000148.md) | [195](/filings/0000759944-24-000176.md) | [193](/filings/0000759944-26-000028.md) | [195](/filings/0000759944-25-000070.md) | [193](/filings/0000759944-25-000108.md) | [197](/filings/0000759944-25-000153.md) | [200](/filings/0000759944-26-000148.md) | [202](/filings/0000759944-26-000101.md) | [208](/filings/0000759944-26-000148.md) |
| Long-term debt | $bn | [17.4](/filings/0000759944-23-000149.md) | [13.5](/filings/0000759944-25-000013.md) | [13.8](/filings/0000759944-24-000090.md) | [13.1](/filings/0000759944-24-000148.md) | [13.9](/filings/0000759944-24-000176.md) | [12.4](/filings/0000759944-26-000028.md) | [12.3](/filings/0000759944-25-000070.md) | [12.5](/filings/0000759944-25-000108.md) | [10.4](/filings/0000759944-25-000153.md) | [11.2](/filings/0000759944-26-000148.md) | [12.3](/filings/0000759944-26-000101.md) | [15.2](/filings/0000759944-26-000148.md) |
| Short-term borrowings | $bn | [0.2](/filings/0000759944-23-000149.md) | [0.5](/filings/0000759944-25-000013.md) | [0.0](/filings/0000759944-24-000090.md) | [0.0](/filings/0000759944-24-000148.md) | [0.0](/filings/0000759944-24-000176.md) | [0.0](/filings/0000759944-26-000028.md) | [0.0](/filings/0000759944-25-000070.md) | [0.2](/filings/0000759944-25-000108.md) | [0.2](/filings/0000759944-25-000153.md) | [0.1](/filings/0000759944-26-000148.md) | [0.1](/filings/0000759944-26-000101.md) | [1.2](/filings/0000759944-26-000148.md) |
| Shareholders' equity | $bn | [22.9](/filings/0000759944-24-000176.md) | [24.3](/filings/0000759944-26-000028.md) | [23.8](/filings/0000759944-25-000108.md) | [23.9](/filings/0000759944-25-000153.md) | [24.9](/filings/0000759944-25-000153.md) | [24.3](/filings/0000759944-26-000148.md) | [24.9](/filings/0000759944-26-000148.md) | [25.2](/filings/0000759944-26-000148.md) | [25.8](/filings/0000759944-25-000153.md) | [26.3](/filings/0000759944-26-000148.md) | [26.2](/filings/0000759944-26-000148.md) | [26.2](/filings/0000759944-26-000148.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,015 d](/filings/0000759944-24-000176.md) | [670 d](/filings/0000759944-26-000028.md) | [554](/filings/0000759944-25-000070.md) | [834 d](/filings/0000759944-25-000108.md) | [130 d](/filings/0000759944-25-000153.md) | [483 d](/filings/0000759944-26-000028.md) | [(213)](/filings/0000759944-26-000101.md) | [886 d](/filings/0000759944-26-000148.md) | [1,696 d](/filings/0000759944-25-000153.md) | [(158) d](/filings/0000759944-26-000028.md) | [237](/filings/0000759944-26-000101.md) | [726 d](/filings/0000759944-26-000148.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [199](/filings/0000759944-24-000176.md) | [199 d](/filings/0000759944-26-000028.md) | [197](/filings/0000759944-25-000070.md) | [194](/filings/0000759944-25-000108.md) | [190](/filings/0000759944-25-000153.md) | [769](/filings/0000759944-25-000013.md) | [186](/filings/0000759944-26-000101.md) | [185](/filings/0000759944-26-000148.md) | [184](/filings/0000759944-25-000153.md) | [200 d](/filings/0000759944-26-000028.md) | [198](/filings/0000759944-26-000101.md) | [198](/filings/0000759944-26-000148.md) |
| Share repurchases | $m | [250 d](/filings/0000759944-24-000176.md) | [0.0 d](/filings/0000759944-26-000028.md) | [300](/filings/0000759944-25-000070.md) | [200 d](/filings/0000759944-25-000108.md) | [325 d](/filings/0000759944-25-000153.md) | [225 d](/filings/0000759944-26-000028.md) | [200](/filings/0000759944-26-000101.md) | [200 d](/filings/0000759944-26-000148.md) | [75.0 d](/filings/0000759944-25-000153.md) | [125 d](/filings/0000759944-26-000028.md) | [300](/filings/0000759944-26-000101.md) | [225 d](/filings/0000759944-26-000148.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [497](/filings/0000759944-23-000149.md) | [488](/filings/0000759944-24-000090.md) | [481](/filings/0000759944-24-000148.md) | [471](/filings/0000759944-24-000176.md) | [464](/filings/0000759944-25-000070.md) | [457](/filings/0000759944-25-000108.md) | [450](/filings/0000759944-25-000153.md) | [442](/filings/0000759944-26-000101.md) | [437](/filings/0000759944-26-000148.md) | [435](/filings/0000759944-25-000153.md) | [430](/filings/0000759944-26-000101.md) | [427](/filings/0000759944-26-000148.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 421,176,788 at 2026-07-24, from the cover of the [10-Q filed 2026-08-03](/filings/0000759944-26-000148.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.